J Marie Suga
Hematology & Oncology · Vallejo, CANPI 1972710119
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Janssen Research & Development, LLC at 33.6% of the total. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.
Across 5 payments — averaging $89.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$150
- Astrazeneca UK Limited$135
- Genentech USA, Inc.$77
- E.r. Squibb & Sons, L.L.C.$50
- Merck$35
Across 749 payments — averaging $9162.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$2.1M
- Seagen Inc.$1.3M
- Merck$753K
- F. Hoffmann-la Roche AG$560K
- Pfizer$463K
- Eli Lilly$437K
- plus $1.3M from 9 others
What the payments were for
- Food & beverage$447100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 1 | $150 |
| Astrazeneca UK Limited | 1 | $135 |
| Genentech USA, Inc. | 1 | $77 |
| E.r. Squibb & Sons, L.L.C. | 1 | $50 |
| Merck | 1 | $35 |
How this compares
$447 in reported general payments places this provider in the 20th percentile of 1,363 hematology & oncology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 88 | $1,488,073 |
| BrukinsaZanubrutinib | 29 | $381,499 |
| XtandiEnzalutamide | 27 | $328,344 |
| VerzenioAbemaciclib | 15 | $238,633 |
| IbrancePalbociclib | 14 | $218,962 |
| InlytaAxitinib | 11 | $175,114 |
| Lenalidomide | 14 | $170,236 |
| GilotrifAfatinib Dimaleate | 11 | $141,438 |
| BraftoviEncorafenib | 11 | $108,883 |
| NivestymFilgrastim-Aafi | 22 | $14,087 |
| Anastrozole | 46 | $1,294 |
| Hydroxyurea | 19 | $805 |
| Imatinib Mesylate | 11 | $786 |
| ComproProchlorperazine | 13 | $671 |
| Tamoxifen Citrate | 24 | $631 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Vallejo
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.